Context Therapeutics Inc. (CNTX): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Context Therapeutics Inc. (CNTX) surge como una fuerza pionera en la oncología de precisión, revolucionando el tratamiento del cáncer a través de un modelo de negocio innovador que navega estratégicamente el complejo panorama del desarrollo terapéutico dirigido. Al aprovechar la experiencia científica patentada y un enfoque enfocado para los tratamientos contra el cáncer resistentes a las hormonas, la compañía se posiciona a la vanguardia de la investigación médica transformadora, prometiendo posibles avances para pacientes que enfrentan malignas desafiantes en la etapa avanzada. Su lienzo de modelo de negocio meticulosamente elaborado revela una estrategia integral que entrea en investigación de vanguardia, asociaciones estratégicas y un compromiso implacable para mejorar los resultados de los pacientes en el mercado oncológico exigente.

Context Therapeutics Inc. (CNTX) - Modelo de negocio: asociaciones clave

Colaboraciones con instituciones de investigación académica

Context Therapeutics ha establecido colaboraciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Estado de colaboración
Fox Chase Cancer Center	Investigación oncológica	Asociación activa
Universidad de Pensilvania	Oncología de precisión	Colaboración de investigación en curso

Asociaciones estratégicas con compañías farmacéuticas centradas en la oncología

Context Therapeutics ha desarrollado asociaciones estratégicas para avanzar en su oleoducto de desarrollo de medicamentos oncológicos:

• Acuerdo de desarrollo de codegado potencial con Merck KGAA para CNTX-6470
• Investigación colaborativa con Novartis sobre terapias de oncología dirigidas

Organizaciones de investigación por contrato (CRO) para el apoyo de ensayos clínicos

La compañía ha contratado los siguientes CRO para la gestión del ensayo clínico:

Nombre de Cro	Fase de ensayo clínico	Alcance del servicio
IQVIA	PRUEBAS FASE 1/2	Reclutamiento de pacientes y gestión del ensayo
Parexel International	Apoyo de prueba de oncología	Cumplimiento regulatorio y gestión de datos

Posibles acuerdos de licencia para el desarrollo de fármacos

Context Therapeutics está explorando oportunidades de licencia para sus candidatos a drogas:

• CNTX-6470: Discusiones potenciales de licencia con compañías farmacéuticas internacionales
• Negociaciones continuas para los derechos globales a la nueva terapéutica oncológica

A partir del cuarto trimestre de 2023, la compañía ha asignado aproximadamente $ 2.5 millones a actividades de asociación y colaboración.

Context Therapeutics Inc. (CNTX) - Modelo de negocio: actividades clave

Investigación y desarrollo de drogas oncológicas

Context Therapeutics se centra en el desarrollo de terapias específicas para los cánceres de mujeres. A partir de 2024, la compañía tiene 2 candidatos de drogas principales en desarrollo:

• ONA-XR para cáncer de mama positivo para receptores hormonales
• CTIM-76 para cáncer de ovario

Gestión y ejecución del ensayo clínico

Etapa de ensayo clínico	Número de pruebas activas	Inscripción del paciente
Fase 1	1	25 pacientes
Fase 2	1	45 pacientes

Investigación preclínica y traslacional

Inversión de investigación en 2023: $ 4.2 millones

• Investigación de orientación molecular
• Identificación de biomarcador
• Mecanismo de estudios de acción

Gestión y protección de la propiedad intelectual

Portafolio de patentes totales: 7 patentes otorgadas

Tipo de patente	Número de patentes	Cobertura geográfica
Composición de la materia	3	EE. UU., EU, Japón
Método de uso	4	Nosotros, EU

Cumplimiento regulatorio y procesos de aprobación de medicamentos

Presentaciones regulatorias en 2023-2024: 2 Aplicaciones de Ind (Investigational New Drug)

• Reuniones de interacción de la FDA: 3
• Consultas regulatorias en curso

Context Therapeutics Inc. (CNTX) - Modelo de negocio: recursos clave

Experiencia científica patentada en terapéutica del cáncer

Context Therapeutics se centra en la oncología de precisión con experiencia especializada en cánceres de hormonas. El equipo científico de la compañía ha desarrollado terapias específicas específicamente para cánceres de mujeres.

Área de enfoque científico	Experiencia específica
Cánceres hormonales	Terapias dirigidas por receptores de progesterona
Especialización de investigaciones	Tratamientos de oncología ginecológica avanzada

Canal de desarrollo de medicamentos innovadores

Context Therapeutics mantiene una tubería de desarrollo de fármacos enfocado dirigido a indicaciones específicas de cáncer.

• Producto de plomo: Terapia CAR-T CLDN6 para tumores sólidos
• Ensayos clínicos en curso en múltiples tipos de cáncer
• Candidatos terapéuticos de etapa preclínica avanzada

Cartera de propiedades intelectuales

La propiedad intelectual de la compañía representa un recurso clave crítico para su modelo de negocio.

Categoría de IP	Número de activos
Solicitudes de patentes	7 familias de patentes activas
Acuerdos de licencia exclusivos	2 plataformas de tecnología estratégica

Investigación e instalaciones de laboratorio

Context Therapeutics mantiene una infraestructura de investigación especializada para apoyar el desarrollo de fármacos.

• Ubicado en Filadelfia, Pensilvania
• Aproximadamente 3,500 pies cuadrados de espacio de laboratorio
• Equipo avanzado de biología molecular y investigación del cáncer

Equipo de gestión y científico experimentado

El capital humano de la compañía representa un recurso clave significativo en su modelo de negocio.

Categoría de equipo	Número de profesionales
Total de empleados	24 a partir de 2024
Investigadores a nivel de doctorado	8 personal científico senior
Ejecutivos de gestión	5 miembros de liderazgo senior

Context Therapeutics Inc. (CNTX) - Modelo de negocio: propuestas de valor

Tratamientos de oncología de precisión dirigidos

Context Therapeutics se centra en desarrollar tratamientos de oncología de precisión con objetivos moleculares específicos. A partir de 2024, los candidatos de productos principales de la compañía incluyen:

Producto	Tipo de cáncer	Etapa de desarrollo	Población de pacientes objetivo
Contessa	Cáncer de mama resistente a las hormonas	Ensayo clínico de fase 2	Aproximadamente 30,000 pacientes anualmente
Orinovo	Cáncer de ovario	Etapa preclínica	Estimado de 22,280 casos nuevos en 2024

Enfoques novedosos para tratar cánceres resistentes a las hormonas

Context Therapeutics ha desarrollado estrategias terapéuticas innovadoras dirigidas a mecanismos de cáncer resistentes a las hormonas.

• Dirección molecular del componente de membrana del receptor de progesterona 1 (PGRMC1)
• Mecanismo único para inhibir la proliferación de células cancerosas
• Aplicación potencial en múltiples tipos de cáncer dependientes de hormonas

Mejoras potenciales en los resultados del paciente

Los datos clínicos demuestran un potencial terapéutico prometedor:

Métrico	Resultados del ensayo clínico de Contessa
Tasa de respuesta general	35.7%
Supervivencia libre de progresión	4.2 meses
Población de pacientes direccionable	Pacientes con cáncer de mama positivo para el receptor hormonal

Soluciones terapéuticas innovadoras para poblaciones de pacientes con cáncer desatendidos

Context Therapeutics se dirige a segmentos de pacientes con opciones de tratamiento limitadas:

• Pacientes de cáncer de mama triple negativo
• Pacientes con cáncer de mama resistente a las hormonas
• Pacientes con cáncer de ovario de etapa avanzada

Centrarse en las terapias de cáncer de etapa avanzada

Investigación y desarrollo de la inversión en tratamientos de oncología avanzada:

Métrica financiera	Valor 2024
Gasto de I + D	$ 12.4 millones
Presupuesto de ensayo clínico	$ 7.6 millones
Tubería de desarrollo terapéutico	3 programas activos

Context Therapeutics Inc. (CNTX) - Modelo de negocios: relaciones con los clientes

Compromiso directo con proveedores de atención médica oncológica

Context Therapeutics mantiene estrategias de participación directa con proveedores de atención médica de oncología a través de interacciones específicas:

Método de compromiso	Frecuencia	Especialistas en el objetivo
Consultas médicas individuales	Trimestral	Oncólogos ginecológicos
Plataformas de comunicación digital	Mensual	Centros de investigación de oncología
Intercambio de datos clínicos personalizados	Bimensual	Instituciones médicas académicas

Programas de apoyo y educación del paciente

Las iniciativas de apoyo centradas en el paciente incluyen:

• Recursos integrales de información del paciente
• Seminarios educativos en línea
• Materiales de orientación de tratamiento personalizado
• Redes de apoyo para participantes de ensayos clínicos

Presentaciones de comunicación científica y conferencia médica

Tipo de conferencia	Presentaciones anuales	Alcance de la audiencia
Simposios de investigación de oncología	4-6 Presentaciones	500-750 especialistas
Conferencias internacionales de cáncer	2-3 presentaciones	1,000-1,500 investigadores

Asociaciones de investigación colaborativa

La red de colaboración de investigación incluye:

• 3 Centros de investigación médica académica
• 2 instituciones de investigación farmacéutica
• 1 Consorcio Nacional de Investigación del Cáncer

Informes de ensayos clínicos transparentes

Canal de informes	Frecuencia	Métricas de transparencia
Clinicaltrials.gov	Actualizaciones trimestrales	100% Cumplimiento
Publicaciones revisadas por pares	2-3 presentaciones anuales	Divulgación de datos integral
Comunicaciones de los inversores	Informes bi-anuales	Datos detallados de progresión de prueba

Context Therapeutics Inc. (CNTX) - Modelo de negocio: canales

Ventas directas a instituciones de atención médica

Context Therapeutics emplea un enfoque de ventas directo dirigido a las instituciones de salud que se especializan en oncología. A partir del cuarto trimestre de 2023, el equipo de ventas directas de la compañía consta de 7 representantes de ventas de oncología especializada.

Canal de ventas	Número de instituciones específicas	Alcance potencial
Centros de investigación de oncología	42	Cobertura nacional
Centros de cáncer integrales	23	Principales áreas metropolitanas

Presentaciones de conferencia médica

La terapéutica de contexto se presenta activamente en conferencias de oncología clave para mostrar la investigación y los desarrollos clínicos.

• Reunión anual de la Asociación Americana de Investigación del Cáncer (AACR)
• Conferencia anual de la Sociedad Americana de Oncología Clínica (ASCO)
• Simposio de cáncer de mama de San Antonio

Publicaciones científicas

La compañía mantiene una sólida estrategia de publicación científica con 6 publicaciones revisadas por pares en 2023.

Tipo de publicación	Número de publicaciones	Rango de factores de impacto
Revistas revisadas por pares	6	2.5 - 7.2

Comunicaciones de relaciones con los inversores

Context Therapeutics utiliza múltiples canales de comunicación de inversores:

• Llamadas de ganancias trimestrales
• Reunión anual de accionistas
• Presentaciones de inversores
• Presentación de la SEC

Plataformas de marketing digital y científica

La compañía aprovecha las plataformas digitales para alcance científico y profesional.

Plataforma digital	Seguidores/suscriptores	Tasa de compromiso
LinkedIn	3,450	4.2%
Gorjeo	2,100	3.7%
Seminarios web científicos	875 participantes registrados	Tasa de asistencia del 62%

Context Therapeutics Inc. (CNTX) - Modelo de negocio: segmentos de clientes

Oncólogos y especialistas en tratamiento del cáncer

Tamaño del mercado objetivo: 18,500 oncólogos en los Estados Unidos a partir de 2023

Características de segmento	Alcance potencial
Centros médicos académicos	285 centros de cáncer especializados
Prácticas de oncología privada	2,300 prácticas especializadas

Centros de tratamiento de hospital y cáncer

Mercado total direccionable: 1.400 instalaciones de tratamiento del cáncer en los Estados Unidos

• Centros de cáncer integrales designados por el Instituto Nacional del Cáncer: 52
• Centros de cáncer comunitario: 1.200
• Instalaciones de tratamiento de oncología especializada: 148

Pacientes con cánceres resistentes a las hormonas

Demografía de la población de pacientes objetivo:

Tipo de cáncer	Casos diagnosticados anuales
Cáncer de mama resistente a las hormonas	48,000 pacientes
Cáncer de próstata resistente a las hormonas	35,000 pacientes

Instituciones de investigación farmacéutica

Institución de investigación panorama:

• Institutos Nacionales de Salud (NIH) Centros de investigación de oncología financiados: 68
• Centros de investigación del cáncer afiliados a la universidad: 112
• Fundamentos de investigación privada centrándose en oncología: 45

Potencios de socios farmacéuticos

Potencial de asociación farmacéutica:

Categoría de socio	Número de socios potenciales
Grandes compañías farmacéuticas	20 empresas globales centradas en la oncología
Compañías de biotecnología de tamaño mediano	87 empresas de oncología especializadas
Startups de oncología respaldadas por la empresa	135 empresas emergentes

Context Therapeutics Inc. (CNTX) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Context Therapeutics Inc. reportó gastos de I + D de $ 12.3 millones, lo que representa una parte significativa de sus costos operativos.

Año fiscal	Gastos de I + D	Porcentaje de gastos totales
2022	$ 10.7 millones	65.4%
2023	$ 12.3 millones	68.2%

Costos de ensayo clínico

Los gastos de ensayos clínicos para la terapéutica del contexto en 2023 totalizaron aproximadamente $ 8.5 millones, centrados en su tubería oncológica.

• Pruebas de fase I: $ 3.2 millones
• Pruebas de fase II: $ 5.3 millones

Protección de propiedad intelectual

La compañía invirtió $ 1.1 millones en costos de presentación y mantenimiento de patentes durante 2023.

Categoría de IP	Costo	Número de patentes
Presentación de patentes	$650,000	7 nuevas patentes
Mantenimiento de patentes	$450,000	12 patentes existentes

Inversiones de cumplimiento regulatorio

Los gastos de cumplimiento regulatorio para 2023 fueron de $ 2.4 millones, que cubren las interacciones de la FDA y los requisitos de documentación.

Adquisición de personal y talento científico

Los costos de personal para la terapéutica del contexto en 2023 ascendieron a $ 15.6 millones, con un enfoque en el talento científico y de investigación.

Categoría de empleado	Número de empleados	Compensación total
Investigar científicos	42	$ 7.8 millones
Desarrollo clínico	23	$ 4.5 millones
Personal administrativo	15	$ 3.3 millones

Context Therapeutics Inc. (CNTX) - Modelo de negocios: flujos de ingresos

Ingresos potenciales de licencia de medicamentos futuros

A partir del cuarto trimestre de 2023, el contexto Therapeutics tiene posibles ingresos por licencia de medicamentos para su activo de oncología principal Contx-101, dirigida a la vía CXCR4/CXCL12 en el cáncer de ovario.

Activo de drogas	Valor de licencia potencial	Mercado objetivo
Contx-101	Tarifa de licencia inicial potencial de $ 12-15 millones	Tratamiento del cáncer de ovario

Acuerdos de asociación estratégica

Context Therapeutics tiene acuerdos de asociación estratégica centrados en la investigación y el desarrollo de oncología.

• Asociaciones de investigación académica con valor estimado en $ 500,000- $ 750,000 anualmente
• Acuerdos potenciales de colaboración farmacéutica

Subvenciones de investigación gubernamental y privada

La compañía ha obtenido fondos de investigación de múltiples fuentes.

Fuente de subvenciones	Monto de financiación	Año
Institutos Nacionales de Salud (NIH)	$ 1.2 millones	2023
Fundación de investigación de oncología privada	$650,000	2023

Pagos potenciales de hitos

Context Therapeutics anticipa los pagos de hitos de los esfuerzos de investigación colaborativa.

• Pagos de hito preclínico: $ 250,000- $ 500,000
• Pagos de avance del ensayo clínico: $ 1-2 millones por hito

Ventas de productos farmacéuticos futuros

Ventas de productos farmacéuticos proyectados para Contx-101 en desarrollo.

Producto	Ventas anuales proyectadas	Potencial de mercado
Contx-101	$ 5-10 millones Entrada de mercado inicial	Mercado de tratamiento del cáncer de ovario

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Value Propositions

You're looking at the core value Context Therapeutics Inc. (CNTX) brings to the table in the oncology space as of late 2025. It all centers on their T cell engaging (TCE) bispecific antibodies, designed to redirect the body's own T cells to attack solid tumors, which is a tough nut to crack for many therapies.

The primary value is in the pipeline itself, which is focused on three distinct, fully humanized TCE assets, each targeting a specific, highly relevant tumor-associated antigen. This diversification across targets is key to capturing value in multiple difficult-to-treat cancer populations.

The portfolio is built around addressing high unmet medical needs in cancers where other approaches have struggled due to safety or efficacy issues. For instance, with CTIM-76, Context Therapeutics is targeting CLDN6-positive cancers, where there are an estimated 70,000 patients with CLDN6-positive metastatic solid tumors in the United States, and currently, no approved targeted treatment options exist for them.

Here's a breakdown of the specific value propositions tied to the assets:

Asset	Target Antigen	Target Cancers (Examples)	Key Design/Clinical Data Point
CTIM-76	Claudin 6 (CLDN6)	Ovarian, endometrial, testicular	No Cytokine Release Syndrome (CRS) greater than Grade 1 observed as of Q3 2025
CT-95	Mesothelin (MSLN)	Pancreatic, NSCLC, ovarian, mesothelioma, colorectal	Avidity enhanced and affinity tuned to minimize impact of shed MSLN
CT-202	Nectin-4	Bladder, colorectal, lung, breast	pH-dependent design for preferential activity in the tumor microenvironment

The potential for a superior safety profile is a major differentiator, especially for CTIM-76. In the ongoing Phase 1 study as of the October 30, 2025 cutoff, Context Therapeutics reported that no Cytokine Release Syndrome ("CRS") greater than Grade 1 has been observed in any cohort. Also, no dose limiting toxicity ("DLT") has been observed for CTIM-76, and a maximum tolerated dose ("MTD") has not been reached. This favorable safety profile supports continued dose escalation with the goal of deepening RECIST responses.

For CT-95, the value proposition is rooted in its sophisticated engineering to overcome a known biological hurdle. The MSLN protein is overexpressed in approximately 30% of cancers, but a challenge has been the presence of shed MSLN fragments acting as a decoy. CT-95 is engineered with moderate affinity but high avidity for membrane-bound MSLN, specifically intended to minimize this decoy effect. This design is described as avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment. As of late 2025, the Phase 1 trial for CT-95 has enrolled 6 patients and is enrolling Cohort 3, with no CRS greater than Grade 2 observed.

The company's financial stability supports the delivery of these value propositions in the near term. Context Therapeutics reported cash and cash equivalents of $76.9 million as of September 30, 2025, which management expects will be sufficient to fund operations into 2027. This runway is critical for reaching key milestones, such as the anticipated initial data readouts for CTIM-76 and CT-95 in the second quarter/middle of 2026, and the expected regulatory filings for CT-202 in the second quarter of 2026.

The value proposition is further detailed by the current clinical progress:

• CTIM-76 has enrolled 12 patients as of October 30, 2025, and is in Cohort 5 (priming dose 140 micrograms/full dose 560 micrograms).
• CT-95 has enrolled 6 patients as of October 30, 2025, and is in Cohort 3 (priming dose 0.18 µg/kg/full dose 0.6 µg/kg).
• CT-202, targeting Nectin-4, is projected to enter first-in-human trials in Q2 2026.

Finance: draft 13-week cash view by Friday.

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Customer Relationships

You're looking at how Context Therapeutics Inc. (CNTX) manages its relationships with the key groups that drive its clinical and financial success. For a clinical-stage biotech, these relationships are everything; they are the direct line to validation and capital.

High-touch engagement with clinical investigators and key opinion leaders

Engagement here centers on the ongoing clinical trials for CTIM-76 and CT-95. The depth of interaction is reflected in the trial progress and the specific dosing cohorts being managed by investigators.

• CT-95 Phase 1 trial enrolled 6 patients as of the October 30, 2025 cutoff.
• The trial is currently enrolling Cohort 3, using a priming dose of 0.18 µg/kg and a full dose of 0.6 µg/kg.
• The proposed clinical starting dose for CT-95, based on AACR 2025 data, was 0.1 µg/kg.
• The company is advancing CT-95 in patients with MSLN-expressing advanced solid tumors, including ovarian, pancreatic, lung, and mesothelioma cancers.

Direct communication with investors via conferences and press releases

Context Therapeutics Inc. has been active in presenting its progress directly to the investment community, often following key data releases like the Q3 2025 results on November 5, 2025.

Conference Name	Date(s) in Late 2025	Format Mentioned
Stifel 2025 Healthcare Conference	November 12, 2025	Presentation, 1x1 Meetings
Guggenheim 2nd Annual Healthcare Innovation Conference	November 10, 2025	Fireside Chat, 1x1 Meetings
H.C. Wainwright 27th Annual Global Investment Conference	September 8, 2025	Event Mentioned
Cantor Global Healthcare Conference 2025	September 3, 2025	Event Mentioned
Citizens Life Sciences Conference	May 7 - May 8, 2025	Event Mentioned

Replays of webcasts from these events are available on the company website for 90 days.

Scientific dialogue through presentations at major oncology meetings (SITC, AACR)

The scientific community engagement is quantified by the number of presentations at major medical congresses. Context Therapeutics Inc. presented at both SITC and AACR in 2025.

• Presented 2 posters at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, held November 7-9, 2025.
• One SITC poster was a Trial in Progress for CT-95; the other covered preclinical data for CT-202.
• Presented a poster at the American Association for Cancer Research (AACR) Annual Meeting 2025 (April 25-30, 2025) in Chicago, IL.
• The AACR presentation highlighted data supporting the selection of the first-in-human dose for CT-95.

Regulatory interaction with the FDA and other health authorities

Regulatory interaction is tracked by the status of Investigational New Drug (IND) applications and expected filing dates for the pipeline assets.

• CT-95 received IND clearance from the FDA in July 2024.
• Initial Phase 1a data for CT-95 is expected by mid-2026.
• Regulatory filings to support the initiation of a first-in-human trial for CT-202 are expected in the second quarter of 2026.

Dedicated investor relations for public shareholders

The relationship with public shareholders is managed through financial reporting and insider activity, which signals management confidence. The stock trades on NASDAQ GS under the ticker CNTX, with a recent price noted at $1.12.

Financial health underpins this relationship; Context Therapeutics Inc. reported cash and cash equivalents of $83.5 million as of June 30, 2025, which the Company expects will fund operations into 2027.

Insider buying in the six months leading up to late 2025 shows direct investment from leadership:

Insider Role	Shares Purchased	Estimated Value
Chief Executive Officer	100,000	$70,080
Chief Financial Officer	40,010	$25,486

Finance: draft 13-week cash view by Friday.

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Channels

The Channels component of Context Therapeutics Inc.'s business model centers on the specific pathways used to reach clinical investigators, the scientific community, capital markets, the public, and regulatory bodies for its T cell engaging (TCE) bispecific antibody pipeline, including CTIM-76, CT-95, and CT-202.

Clinical trial sites are the primary channel for drug delivery and testing. As of the October 30, 2025 cutoff, the Phase 1 dose escalation study for CT-95 had enrolled 6 patients, with dosing in Cohort 3. The CT-95 clinical trial (NCT06756035) is being conducted at clinical sites in the US. For CTIM-76, the Phase 1 trial had enrolled 12 patients as of the same October 30, 2025 cutoff, with dosing progressing to Cohort 5.

Clinical Program	Status as of October 30, 2025 Cutoff	Dosing Cohort	Enrolled Patients
CTIM-76 (CLDN6 x CD3)	Phase 1 Dose Escalation	Cohort 5	12
CT-95 (MSLN x CD3)	Phase 1 Dose Escalation	Cohort 3	6

Data dissemination to the scientific community relies heavily on presentations at major medical meetings. Context Therapeutics Inc. shared two posters discussing its CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, held November 7-9, 2025, in National Harbor, MD. The company also presented a Trial in Progress poster for the CTIM-76 Phase 1 clinical trial at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in June 2025. Earlier in the year, preclinical data for CT-95 was presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in April 2025.

Access to capital markets is facilitated through participation in key investor conferences. Context Therapeutics Inc. confirmed presence at several such events through late 2025 and into November 2025.

• Guggenheim 2nd Annual Healthcare Innovation Conference: November 10-12, 2025.
• Stifel 2025 Healthcare Conference: November 11-13, 2025.
• Citizens Life Sciences Conference: May 7-8, 2025.
• 24th Annual Needham Virtual Healthcare Conference: April 7-10, 2025.

Public and investor updates are channeled through the corporate website and social media presence. The company's corporate website is www.contexttherapeutics.com, with investor relations information available at https://ir.contexttherapeutics.com. Context Therapeutics also follows and provides updates on X (formerly Twitter) and LinkedIn. The latest reported financial data as of late 2025 shows cash and cash equivalents of $76.9 million as of September 30, 2025, with the company expecting this to fund operations into 2027. Research and development expenses for the third quarter of 2025 were $8.7 million.

Direct regulatory submissions to health agencies, such as the U.S. Food and Drug Administration (FDA), represent a critical channel for advancing drug candidates. Context Therapeutics expects to complete the necessary regulatory filings to support the initiation of a first-in-human trial for CT-202 in the second quarter of 2026.

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Customer Segments

You're looking at the key groups Context Therapeutics Inc. (CNTX) needs to satisfy to move its pipeline forward. For a clinical-stage biotech, these segments are less about mass-market consumers and more about specialized partners and capital providers. Here's the breakdown as of late 2025.

Patients with advanced solid tumors expressing CLDN6, MSLN, or Nectin-4

This segment is defined by biomarker expression, not just a specific cancer type, though Context Therapeutics Inc. (CNTX) is focused on several indications. The potential patient pool is defined by the targets of their three main assets.

• Mesothelin (MSLN) is overexpressed in approximately 30% of cancers.
• CTIM-76 targets CLDN6-positive ovarian, endometrial, and testicular cancers.
• CT-202 targets Nectin-4, which is highly expressed in bladder, colorectal, lung, and breast tumors.

Oncologists and clinical investigators running Phase 1 trials

These are the gatekeepers who enroll patients and execute the trials. Their focus is on safety, tolerability, and early efficacy signals. Context Therapeutics Inc. (CNTX) is actively engaging this group with ongoing dose-escalation studies.

Here's the quick math on where the two lead programs stood as of the October 30, 2025 cutoff:

Asset	Target Biomarker	Patients Enrolled (as of Oct 30, 2025)	Current Cohort	Key Safety/Efficacy Note
CTIM-76	CLDN6	12 patients	Cohort 5	Preliminary RECIST response observed beginning at Cohort 3; No CRS greater than Grade 1; MTD not reached
CT-95	MSLN	6 patients	Cohort 3	Approaching target dose exposure (projected at Cohort 4); No DLT observed; No CRS greater than Grade 2

The broader ecosystem supporting these investigators is large; for context, in the first half of 2025, 1,560 new Phase 1 interventional trials started globally. Also, a major early-phase research network like START operates with 31 Principal Investigators across its sites.

Future pharmaceutical companies seeking oncology assets for acquisition or co-development

This segment is interested in the value of Context Therapeutics Inc. (CNTX)'s pipeline assets, especially given their recent deal history. They look for de-risked, differentiated assets.

• CT-95 was acquired via a Corporate Asset Purchase from Link Immunotherapeutics on 09-Jul-2024.
• CT-202 was in-licensed from BioAtla, Inc. in September 2024.
• The company has an expected cash runway into 2027, suggesting operational stability for near-term partnership discussions.

Institutional and retail investors in the biotechnology sector

This group provides the necessary capital to fund the clinical development. Their interest is tied to the stock performance and ownership structure. As of November 2025, the ownership structure shows significant influence from sophisticated capital pools.

The ownership makeup as of November 11, 2025, looks like this:

Investor Group	Approximate Ownership Stake
Private Equity Firms	46%
Institutions (General)	22% (cut of recent gains)
General Public/Retail Investors	20% stake
Hedge Funds	10%

The company's market capitalization stood at $100M as of November 4, 2025, with approximately 91.9M shares outstanding. Context Therapeutics Inc. (CNTX) reported cash and cash equivalents of $76.9 million as of September 30, 2025, against a Q3 2025 net loss of $9.7 million. The stock price on November 4, 2025, was $1.11.

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Cost Structure

You're looking at the cost side of Context Therapeutics Inc.'s (CNTX) operations as they push their pipeline through clinical stages. For a clinical-stage biotech, the costs are heavily weighted toward science and trials, which is exactly what the numbers show.

The most significant recurring cost driver is Research and Development (R&D). Context Therapeutics reported high R&D expenses, totaling $7.8 million in the second quarter of 2025, up substantially from $1.4 million in the second quarter of 2024. This spending reflects the active advancement of their clinical assets.

Clinical trial costs are central to this R&D spend. The progression of the two lead candidates through their Phase 1 dose escalation studies is a major expense component. For instance, in Q2 2025, the R&D increase was driven by higher expenses for CT-202 ($3.1 million), CT-95 ($1.5 million), and CTIM-76 ($0.1 million) compared to the prior year period. The CT-95 trial, which started in Q2 2025, is a key cost center, as is the ongoing CTIM-76 study.

General and administrative (G&A) expenses are much lower but still present a fixed cost base. For the third quarter of 2025, G&A expenses were approximately $1.9 million. This is consistent with the second quarter of 2025, where G&A was also $1.9 million, up from $1.7 million in Q2 2024.

Personnel costs are a direct driver of both R&D and G&A increases. You see this reflected in the year-over-year comparisons. In Q3 2025, personnel-related costs within R&D were up by $0.7 million compared to Q3 2024. Looking at Q2 2025, personnel-related costs increased by $1.6 million year-over-year, primarily due to higher headcount and termination benefits related to employee departures. In Q1 2025, personnel costs were up by $0.5 million year-over-year, also due to higher headcount and compensation adjustments.

The costs associated with building the pipeline, specifically in-licensing and acquisition costs, were significant in the prior year but now manifest as ongoing R&D expenses. Context Therapeutics incurred in-process research and development charges totaling $14.75 million in the third quarter of 2024, which covered the acquisition of CT-95 (July 2024) and the in-licensing of CT-202 (September 2024). These upfront costs are now capitalized or expensed, driving the current period R&D.

Here's a quick look at how the quarterly operating expenses stack up for the most recent periods we have data for:

Expense Category	Q2 2025 Amount	Q3 2025 Amount	Primary Driver
Research and Development (R&D)	$7.8 million	$8.7 million	Clinical trial progression (CTIM-76, CT-95)
General and Administrative (G&A)	$1.9 million	$1.9 million	Headcount, professional fees
Net Loss	$8.8 million	$9.7 million	High operating spend

The R&D spend is clearly the engine of the cost structure, which is typical for a company focused on advancing novel T cell engaging bispecific antibodies. You can see the direct impact on the bottom line, with the Q2 2025 net loss at $8.8 million and the Q3 2025 net loss at $9.7 million.

The key components driving the R&D burn rate are:

• Higher CT-202 expense of $3.1 million in Q2 2025.
• Higher CT-95 expense of $1.5 million in Q2 2025.
• CTIM-76 expense showed a decrease of $0.8 million in Q1 2025 due to lower manufacturing/preclinical costs.
• CT-95 and CT-202 acquisition/licensing costs totaled $14.75 million in Q3 2024 charges.

Finance: draft 13-week cash view by Friday.

Context Therapeutics Inc. (CNTX) - Canvas Business Model: Revenue Streams

You're hiring before product-market fit, which for a clinical-stage biotech like Context Therapeutics Inc., means your revenue streams are almost entirely non-product based right now. Honestly, this is the expected reality for a company advancing novel therapeutics through trials.

Currently, Context Therapeutics Inc. has zero product revenue, which is typical for a clinical-stage biotech focused on developing its pipeline candidates like CTIM-76 and CT-95. The primary, though non-operational, income source as of late 2025 comes from managing its balance sheet.

Specifically, for the third quarter ending September 30, 2025, Context Therapeutics Inc. earned other income of approximately $0.9 million. This figure is largely comprised of interest income earned on its cash and cash equivalents. To give you context on the cash position supporting this, the company held $76.9 million in cash and cash equivalents as of September 30, 2025. Management has stated they expect this cash position to be sufficient to fund operations into 2027.

Here's a quick look at the key financial data points relevant to the current revenue and funding picture:

Financial Metric	Amount/Status (As of Q3 2025)	Source/Context
Product Sales Revenue (TTM)	null	Context Therapeutics has no revenue
Interest Income (Q3 2025)	$0.9 million	Reported in Q3 2025 Financial Results
Cash & Equivalents (Sept 30, 2025)	$76.9 million	Sufficient to fund operations into 2027
Net Loss (Q3 2025)	$9.7 million	Improvement from $17.5 million loss in Q3 2024
Latest Equity Raise (Post IPO)	$100M	May 06, 2024

Beyond the current interest income, the true potential revenue streams for Context Therapeutics Inc. are tied to the success of its clinical pipeline, which manifests through licensing agreements and future commercialization.

The company has agreements in place that provide for future milestone payments. For instance, the amended collaboration and licensing agreement with Integral Molecular, Inc. for CTIM-76 outlines specific potential payments:

• Aggregate development and regulatory milestone payments reduced to $15 million.
• Aggregate sales milestone payments reduced to $12.5 million.
• A flat royalty rate of 6% on net sales, beginning no sooner than February 1, 2034.

These future product sales or commercialization royalties are contingent upon several regulatory achievements, including:

• First patient's first screening visit in a Phase 1b/2 or Phase 2 clinical trial for CTIM-76.
• First patient's first screening visit in a Phase 3 clinical trial for CTIM-76.
• United States marketing approval for CTIM-76.
• European Union marketing approval for CTIM-76.
• United Kingdom marketing approval for CTIM-76.
• Japan marketing approval for CTIM-76.

Finally, the operational funding itself is a key component of the current financial model, which relies on equity financing rounds to bridge the gap until a product is commercialized. The company raised $100M in a Post IPO round on May 06, 2024. This capital, combined with the existing cash balance, is what management is using to fund operations into 2027. Finance: draft 13-week cash view by Friday.